V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005841 | 330002768 | 1.78 | 109.5 | Palliative (P) | 2015-09-22 | 2015-09-22 | CNS Low Grade Glioma Vinblastine | null | null | 330025052 | VINCRISTINE |
| 330005842 | 330002769 | 1.77 | null | Palliative (P) | 2016-12-21 | 2016-12-29 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 330000176 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330005843 | 330002770 | null | 19.5 | Curative (C) | null | 2016-02-26 | EDP | N | N | 330000188 | AML17 TRIAL |
| 330005844 | 330002770 | 1.83 | 75 | Curative (C) | 2016-08-12 | 2016-08-24 | RCEOP | N | N | 330000188 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330005845 | 330002771 | null | 67.25 | null | 2017-01-14 | 2017-01-14 | Azacitidine | Y | N | 330000343 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005846 | 330002772 | 1.72 | 76.9 | null | 2016-01-17 | 2016-01-29 | CHOP | 02 | N | 330000411 | PEMBROLIZUMAB |
| 330005847 | 330002773 | 1.7 | 113.8 | Palliative (P) | 2013-06-08 | 2013-06-11 | Azacitidine | N | N | 330000481 | CHLORAMBUCIL |
| 330005848 | 330007511 | 1.82 | 62.5 | Curative (C) | 2015-05-11 | 2015-05-20 | Docetaxel + Gemcitabine with GCSF | 02 | N | 330000507 | VIDE |
| 330005849 | 330010087 | 0 | 76.1 | Palliative (P) | 2014-01-18 | 2014-02-05 | PEMBROLIZUMAB | 1 | N | 330000543 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005850 | 330002774 | 1.67 | 105 | Palliative (P) | null | 2017-04-29 | PACLITAXEL | N | N | 330000556 | DOXORUBICIN + IFOSFAMIDE |
| 330005851 | 330002774 | 1.56 | null | Palliative (P) | 2018-04-28 | 2018-05-04 | FLUOROURACIL + MITOMYCIN + RT | null | null | 330000556 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330005852 | 330002775 | null | 0 | Curative (C) | 2016-05-31 | 2016-05-31 | Doxorubicin + Ifosfamide | 02 | N | 330000681 | MIDOSTAURIN |
| 330005853 | 330002775 | null | null | Curative (C) | 2017-05-26 | 2017-05-26 | TOPOTECAN | N | null | 330000681 | CETUXIMAB + CISPLATIN + FU |
| 330005854 | 330002776 | 1.73 | null | null | 2014-04-10 | 2014-04-10 | Bortezomib (weekly) | N | N | 330000747 | IMATINIB |
| 330005855 | 330002777 | 1.71 | 41.6 | null | 2014-12-10 | 2014-12-25 | R Chlorambucil | Y | null | 330000770 | CHOP R |
| 330005856 | 330002777 | 1.67 | 76.7 | Palliative (P) | null | 2015-11-06 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 330000770 | CHLORAMBUCIL |
| 330005857 | 330002778 | null | null | null | 2018-11-20 | 2018-12-05 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330000864 | VINCRISTINE |
| 330005858 | 330002778 | 1.91 | 72.4 | Curative (C) | 2015-11-04 | 2015-11-04 | FLUOROURACIL + IRINOTECAN | N | null | 330000864 | CISPLATIN + PEMETREXED |
| 330005859 | 330002778 | 1.82 | 89.4 | Palliative (P) | 2016-02-25 | 2016-02-25 | AML 19 TRIAL | 02 | null | 330000864 | AML16 TRIAL |
| 330005860 | 330011511 | 1.74 | 10.8 | Palliative (P) | 2018-04-20 | 2018-05-22 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | Y | 330001076 | CYTARABINE |
| 330005861 | 330012291 | 1.6 | 67 | Palliative (P) | null | 2017-10-30 | PEMBROLIZUMAB | N | N | 330001080 | EP/EMA |
| 330005862 | 330012291 | 1.65 | 50.9 | Adjuvant (A) | 2016-07-27 | 2016-08-11 | CISPLATIN + CYCLO + DOXORUBICIN | N | n | 330001080 | VEMURAFENIB |
| 330005863 | 330002779 | 1.74 | 8.4 | Neo-adjuvant (N) | 2017-07-13 | 2017-08-17 | Methotrexate Intrathecal (any age) | N | N | 330001342 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330005864 | 330002780 | 1.54 | 16.4 | Palliative (P) | 2017-03-22 | 2017-03-31 | PACLITAXEL | N | N | 330001370 | VIDE |
| 330005865 | 330002781 | 1.66 | 66.9 | Palliative (P) | null | 2017-07-21 | Chlorambucil | N | N | 330001610 | NILOTINIB |
| 330005866 | 330002782 | 1.75 | 10.6 | Curative (C) | 2016-02-26 | 2016-03-01 | Carboplatin + Doxorubicin | N | N | 330001639 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330005867 | 330002782 | null | null | Curative (C) | null | 2018-10-05 | CHOP R - 21 days | null | null | 330001639 | CHOP R |
| 330005868 | 330010089 | 0 | 52 | Palliative (P) | 2015-12-08 | 2015-12-14 | Methotrexate + Folinic acid | N | N | 330001714 | CARBOPLATIN + RT |
| 330005869 | 330010089 | 1.61 | 71.5 | Curative (C) | null | 2018-06-03 | UKALL14- Ph 1 Induction | N | null | 330001714 | PEMBROLIZUMAB |
| 330005870 | 330002783 | 1.57 | 59.7 | Adjuvant (A) | 2018-04-18 | 2018-04-18 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | 02 | N | 330002073 | FLUOROURACIL + MITOMYCIN |
| 330005871 | 330002784 | 1.78 | null | Curative (C) | 2018-08-06 | 2018-08-07 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 330002095 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005872 | 330002784 | 0 | 63 | Neo-adjuvant (N) | 2017-04-16 | 2017-04-18 | CARBOPLATIN + RT | 2 | N | 330002095 | BEP |
| 330005873 | 330010090 | 1.48 | 74.35 | Disease modification (D) | 2016-11-23 | 2016-12-06 | CNS LGG 2004 03 vinc weekly+ carbo | 02 | null | 330002306 | CISPLATIN + VINORELBINE |
| 330005874 | 330010090 | null | null | null | null | 2018-05-14 | VAI (Ifos 3g/m2) | null | null | 330002306 | AML17 TRIAL |
| 330005875 | 330002785 | 1.85 | 76 | Disease modification (D) | 2018-09-24 | 2018-09-24 | CYCLOPHOSPHAMIDE + THALIDOMIDE | Y | N | 330002464 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330005876 | 330002785 | null | null | Neo-adjuvant (N) | 2014-07-25 | 2014-08-20 | FLAG + Idarubicin | null | null | 330002464 | CVD |
| 330005877 | 330002786 | 1.7 | null | Curative (C) | 2017-11-12 | 2017-11-18 | Oxaliplatin + Modified de Gramont | 02 | N | 330002539 | BORTEZOMIB |
| 330005878 | 330002787 | 1.67 | 85.7 | Curative (C) | 2017-06-23 | 2017-06-24 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330003175 | PEMBROLIZUMAB |
| 330005879 | 330002787 | 1.68 | 75 | Neo-adjuvant (N) | 2018-03-01 | 2018-03-04 | EDP | 02 | N | 330003175 | MITOTANE |
| 330005880 | 330002787 | null | null | Neo-adjuvant (N) | 2018-06-23 | 2018-06-23 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330003175 | VEIP |
| 330005881 | 330002788 | null | 87.1 | Curative (C) | 2017-09-06 | 2017-10-02 | CARBOPLATIN + RT | Y | N | 330003750 | ETOPOSIDE + RITUXIMAB |
| 330005882 | 330002789 | 1.75 | 96.3 | Neo-adjuvant (N) | 2018-10-23 | 2018-10-25 | CHOP R - 21 days | 02 | N | 330003902 | VINBLASTINE |
| 330005883 | 330002790 | 1.63 | 65.2 | Palliative (P) | 2016-06-14 | 2016-06-23 | Azacitidine | 2 | N | 330003920 | FLAG + IDARUBICIN |
| 330005884 | 330002791 | 1.72 | 80.4 | Curative (C) | null | 2016-11-12 | Bevacizumab | N | N | 330003944 | EDP + MITOTANE |
| 330005885 | 330002792 | null | 62 | Curative (C) | 2019-08-18 | 2019-08-29 | AML16 Azacitidine | 2 | Y | 330003997 | RUXOLITINIB |
| 330005886 | 330002793 | 1.73 | 27.4 | Curative (C) | 2017-08-09 | 2017-08-13 | Hydroxycarbamide | 02 | N | 330004312 | CISPLATIN + DOCETAXEL |
| 330005887 | 330002794 | 1.75 | 70 | Palliative (P) | 2018-04-19 | 2018-05-03 | Hydroxycarbamide | N | N | 330004332 | IFOSFAMIDE + LIPOSOMAL DOXORUBICIN |
| 330005888 | 330002794 | 1.49 | null | Palliative (P) | null | 2016-10-03 | Dacarbazine | 2 | N | 330004332 | CYTARABINE |
| 330005889 | 330010092 | 1.62 | null | null | 2017-10-13 | 2017-10-14 | Ifosfamide | Y | N | 330004392 | CHLORAMBUCIL |
| 330005890 | 330011514 | 1.63 | null | Curative (C) | 2017-08-15 | 2017-08-20 | Azacitidine | N | N | 330004516 | EDP |